Phase 3 Randomized Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Brief description of study
The purpose of the trial is to determine the safety and efficacy of the pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus androgen deprivation therapy (ADT) in participants with metastatic hormone-sensitive prostate cancer (mHSPC). We want to know if one treatment is superior to another when treating participants with metastatic hormone-sensitive prostate cancer.
Clinical Study Identifier: s19-01532
ClinicalTrials.gov Identifier: NCT04191096
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
